C3N-00203
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 72.15058179
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.630
- E2F_TARGETS+0.570
- MYC_TARGETS_V1+0.550
- G2M_CHECKPOINT+0.520
- ALLOGRAFT_REJECTION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.290
- MITOTIC_SPINDLE+0.280
- GLYCOLYSIS+0.270
- INTERFERON_ALPHA_RESPONSE+0.270
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.380
- KRAS_SIGNALING_DN-0.360
- CHOLESTEROL_HOMEOSTASIS-0.330
- BILE_ACID_METABOLISM-0.320
- APICAL_SURFACE-0.240
- COAGULATION-0.240
- ANGIOGENESIS-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.190
- MYOGENESIS-0.180
- ESTROGEN_RESPONSE_EARLY-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | e8381a92.5379.4ece.8414.230d0f0026e1 | — | cohortA1 | 0.888 |
| 2 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.874 |
| 3 | TCGA-ZF-A9RF-01A-11R-A38B-07 | — | — | 0.874 |
| 4 | TCGA-52-7812-01A-11R-2125-07 | — | cohortA1 | 0.873 |
| 5 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.873 |
| 6 | TCGA-AR-A1AI-01A-11R-A12P-07 | — | E | 0.838 |
| 7 | 9a1be9ca-1641-4eac-beb9-3b54ec277a7c | — | — | 0.834 |
| 8 | SRR8518289 | — | E | 0.833 |
| 9 | MNG826 | — | — | 0.828 |
| 10 | TCGA-AN-A0AJ-01A-11R-A00Z-07 | — | C | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |